AstraZeneca PLC (LON:AZN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of £109.31 ($148.07) and traded as high as £121.30 ($164.32). AstraZeneca shares last traded at £119.70 ($162.15), with a volume of 1,129,976 shares changing hands.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on AZN shares. Berenberg Bank reaffirmed a "buy" rating and issued a £142 target price on shares of AstraZeneca in a research report on Monday, September 1st. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a £110 price target on shares of AstraZeneca in a report on Wednesday, July 30th. Finally, Shore Capital reiterated a "buy" rating and set a £135 price target on shares of AstraZeneca in a report on Tuesday, July 29th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, AstraZeneca has an average rating of "Moderate Buy" and a consensus price target of £131.75.
Get Our Latest Stock Report on AstraZeneca
AstraZeneca Trading Down 0.3%
The firm has a market capitalization of £185.01 billion, a price-to-earnings ratio of 2,247.54, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The firm's 50-day simple moving average is £111.45 and its 200 day simple moving average is £109.31.
Insider Buying and Selling
In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. 0.14% of the stock is currently owned by corporate insiders.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
